A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy

International Journal of Cancer

Volumn 139, Issue 1, 2016, Pages 177-186

  Eng, Cathy ^a   Bessudo, Alberto ^b   Hart, Lowell L ^c   Severtsev, Aleksey ^d   Gladkov, Oleg ^e   Müller, Lothar ^e   Kopp, Mikhail V ^e   Vladimirov, Vladimir ^e   Langdon, Robert ^f   Kotiv, Bogdan ^g   Barni, Sandro ^h   Hsu, Ching ⁱ   Bolotin, Ellen ⁱ   Von Roemeling, Reinhard ⁱ   Schwartz, Brian ^j   Bendell, Johanna C ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b CCARE (California Cancer Associates for Research and Excellence)   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d Central Clinical Hospital No 1   (Russian Federation)

^e Chelyabinsk Regional Clinical Oncological Dispensary ^*  (Russian Federation)

^f Methodist Hospital Omaha   (United States)

^g S M KIROV MILITARY MEDICAL ACADEMY   (Russian Federation)

^h TREVIGLIO HOSPITAL   (Italy)

ⁱ DAIICHI SANKYO INC   (United States)

^j ARQULE INC   (United States)

more..

Author keywords

irinotecan; KRAS wild type; MET inhibitor; metastatic colorectal cancer; tivantinib

Indexed keywords

CETUXIMAB; IRINOTECAN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TIVANTINIB; VASCULOTROPIN; 2 PYRROLIDONE DERIVATIVE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; KRAS PROTEIN, HUMAN; PROTEIN P21; QUINOLINE DERIVATIVE;

ABDOMINAL PAIN; ACNE; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEADACHE; HEART DISEASE; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; IMMUNOHISTOCHEMISTRY; INFECTION; INFESTATION; INSOMNIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METASTATIC COLORECTAL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; ONCOGENE K RAS; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; SMALL INTESTINE OBSTRUCTION; STOMATITIS; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS P21(RAS); PYRROLIDINONES; QUINOLINES;

EID: 84963603435     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30049     Document Type: Article

References (59)

1. Benson AB, III., Epidemiology, disease progression, and economic burden of colorectal cancer. J Manag Care Pharm 2007; 13 (suppl c): S5-18.
2. Van Cutsem E, Nordlinger B, Cervantes A, et al., Advanced colorectal cancer: ESMO clinical practice guidelines for treatment. Ann Oncol 2010; 21(suppl5): v93-7.
3. National Cancer Institute. Surveillance, Epidemiology, and End Results Stat Fact sheets: Colon and Rectum Cancer. http://seer.cancer.gov/statfacts/html/colorect.html.
4. Benson AB, III, Bekaii-Saab T, Chan E, et al., Metastatic colon cancer, version 3.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2013; 11: 141-52. quiz 52.
5. Pfeiffer P, Nielsen D, Bjerregaard J, et al., Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008; 19: 1141-5.
6. Douillard JY, Siena S, Cassidy J, et al., Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol 2014; 25: 1346-55.
7. Cunningham D, Humblet Y, Siena S, et al., Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.
8. Bristol-Myers Squibb, Eli Lilly, ImClone. Erbitux (cetuximab) prescribing information 2013. Available at: http://www.drugs.com/pro/erbitux.html.
9. Van Cutsem E, Kohne CH, Hitre E, et al., Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-17.
10. Van Cutsem E, Kohne CH, Lang I, et al., Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-9.
11. Chong CR, Janne PA., The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 2013; 19: 1389-400.
12. Misale S, Yaeger R, Hobor S, et al., Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-6.
13. Chang DZ, Kumar V, Ma Y, et al., Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy. J Hematol Oncol 2009; 2: 18
14. De Roock W, Piessevaux H, De Schutter J, et al., KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008; 19: 508-15.
15. Lievre A, Bachet JB, Boige V, et al., KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-9.
16. Walther A, Johnstone E, Swanton C, et al., Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009; 9: 489-99.
17. Karapetis CS, Khambata-Ford S, Jonker DJ, et al., K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-65.
18. Bardelli A, Corso S, Bertotti A, et al., Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. Cancer Discov 2013; 3: 658-73.
19. Inno A, Di Salvatore M, Cenci T, et al., Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Clin Colorectal Cancer 2011; 10: 325-32.
20. Liska D, Chen CT, Bachleitner-Hofmann T, et al., HGF rescues colorectal cancer cells from EGFR inhibition via MET activation. Clin Cancer Res 2011; 17: 472-82.
21. Luraghi P, Reato G, Cipriano E, et al., MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res 2014; 74: 1857-69.
22. De Oliveira AT, Matos D, Logullo AF, et al., MET is highly expressed in advanced stages of colorectal cancer and indicates worse prognosis and mortality. Anticancer Res 2009; 29: 4807-11.
23. Garouniatis A, Zizi-Sermpetzoglou A, Rizos S, et al., FAK, CD44v6, c-Met and EGFR in colorectal cancer parameters: tumour progression, metastasis, patient survival and receptor crosstalk. Int J Colorectal Dis 2013; 28: 9-18.
24. Liu Y, Li Q, Zhu L., Expression of the hepatocyte growth factor and c-Met in colon cancer: correlation with clinicopathological features and overall survival. Tumori 2012; 98: 105-12.
25. Voutsina A, Tzardi M, Kalikaki A, et al., Combined analysis of KRAS and PIK3CA mutations, MET and PTEN expression in primary tumors and corresponding metastases in colorectal cancer. Mod Pathol 2013; 26: 302-13.
26. Abou-Bakr AA, Elbasmi A., c-MET overexpression as a prognostic biomarker in colorectal adenocarcinoma. Gulf J Oncol 2013; 1: 28-34.
27. Chang HY, Kao MC, Way TD, et al., Diosgenin suppresses hepatocyte growth factor (HGF)-induced epithelial-mesenchymal transition by down-regulation of Mdm2 and vimentin. J Agric Food Chem 2011; 59: 5357-63.
28. Yao YL, Shao J, Zhang C, et al., Proliferation of colorectal cancer is promoted by two signaling transduction expression patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK. PLoS One 2013; 8: e78086
29. Chen HJ, Jiang YL, Lin CM, et al., Dual inhibition of EGFR and c-Met kinase activation by MJ-56 reduces metastasis of HT29 human colorectal cancer cells. Int J Oncol 2013; 43: 141-50.
30. Yap TA, Olmos D, Brunetto AT, et al., Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011; 29: 1271-9.
31. Adjei AA, Schwartz B, Garmey E., Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers. Oncologist 2011; 16: 788-99.
32. Munshi N, Jeay S, Li Y, et al., ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010; 9: 1544-53.
33. Scagliotti GV, Novello S, von Pawel J., The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev 2013; 39: 793-801.
34. Kammula US, Kuntz EJ, Francone TD, et al., Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett 2007; 248: 219-28.
35. Zeng ZS, Weiser MR, Kuntz E, et al., c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett 2008; 265: 258-69.
36. Samame Perez-Vargas JC, Biondani P, Maggi C, et al., Role of cMET in the development and progression of colorectal cancer. Int J Mol Sci 2013; 14: 18056-77.
37. Song N, Liu S, Zhang J, et al., Cetuximab-induced MET activation acts as a novel resistance mechanism in colon cancer cells. Int J Mol Sci 2014; 15: 5838-51.
38. Aoyama A, Katayama R, Oh-Hara T, et al., Tivantinib (ARQ 197) exhibits antitumor activity by directly interacting with tubulin and overcomes ABC transporter-mediated drug resistance. Mol Cancer Ther 2014; 13: 2978-90.
39. Kanteti R, Dhanasingh I, Kawada I, et al., MET and PI3K/mTOR as a potential combinatorial therapeutic target in malignant pleural mesothelioma. PLoS One 2014; 9: e105919
40. Katayama R, Aoyama A, Yamori T, et al., Cytotoxic activity of tivantinib (ARQ 197) is not due solely to c-MET inhibition. Cancer Res 2013; 73: 3087-96.
41. Kumar KS, Tripolitsioti D, Ma M, et al., The Ser/Thr kinase MAP4K4 drives c-Met-induced motility and invasiveness in a cell-based model of SHH medulloblastoma. SpringerPlus 2015; 4: 19
42. Santoro A, Rimassa L, Borbath I, et al., Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol 2013; 14: 55-63.
43. Scagliotti G, von Pawel J, Novello S, et al., Phase III multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non-small-cell lung cancer. J Clin Oncol 2015; 33: 2667-74.
44. Monk P, Liu G, Stadler WM, et al., Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol 2015; 33: Abstract 146.
45. Personeni N, Rimassa L, Verusio C, et al., FOLFIRI and cetuximab every second week for first-line treatment of KRAS wild-type metastatic colorectal cancer according to phosphatase and tensin homolog expression: a phase II study. Clin Colorectal Cancer 2015; 14: 162-9.
46. Tural D, Batur S, Erdamar S, et al., Analysis of PTEN, BRAF and PI3K status for determination of benefit from cetuximab therapy in metastatic colorectal cancer patients refractory to chemotherapy with wild-type KRAS. Tumour Biol 2014; 35: 1041-9.
47. Loupakis F, Pollina L, Stasi I, et al., PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 2009; 27: 2622-9.
48. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, et al., The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 2014; 53: 852-64.
49. Engelman JA, Zejnullahu K, Mitsudomi T, et al., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-43.
50. Sequist LV, von Pawel J, Garmey EG, et al., Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011; 29: 3307-15.
51. Feldman DR, Einhorn LH, Quinn DI, et al., A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Invest New Drugs 2013; 31: 1016-22.
52. Goldman JW, Laux I, Chai F, et al., Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib. Cancer 2012; 118: 5903-11.
53. Kang YK, Muro K, Ryu MH, et al., A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs 2014; 32: 355-61.
54. Trojan J, Zeuzem S., Tivantinib in hepatocellular carcinoma. Expert Opin Investig Drugs 2013; 22: 141-7.
55. de Macedo MP, de Lima LG, Begnami MD, et al., KRAS insertions in colorectal cancer: what do we know about unusual KRAS mutations? Exp Mol Pathol 2014; 96: 257-60.
56. Tong JH, Lung RW, Sin FM, et al., Characterization of rare transforming mutations in sporadic colorectal cancer. Cancer Biol Ther 2014; 15: 768-76.
57. Zorzetto M, Ferrari S, Saracino L, et al., MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications. Transl Lung Cancer Res 2012; 1: 194-207.
58. SCRI Development Innovations LLC, Daiichi Sankyo Inc. A phase I/II trial of the c-Met inhibitor, tivantinib, in combination with FOLFOX for the treatment of patients with advanced solid tumors (phase I) and previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach (phase II). http://www.clinicaltrials.gov/ct2/show/NCT01611857?term=NCT01611857&rank=1.
59. Santoro A, Rimassa L., A single-arm phase II study of tivantinib (ARQ 197) plus cetuximab in EGFR inhibitor-resistant MET high subjects with locally advanced or metastatic colorectal cancer with wild-type KRAS. http://www.clinicaltrials.gov/ct2/show/NCT01892527?term=tivantinib&cond=colorectal&rank=2.